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Abstract
A particularly challenging subpopulation of prostate cancer patients are those who present with a
persistently elevated PSA and suspicion of prostate cancer despite having had one or more prior negative
prostate biopsies. These patients may benefit from the improvements made in prostate imaging through
multiparametric MRI (mpMRI) and MRI-guided prostate biopsy techniques. In this study, we evaluate mpMRI
and MRI-US fusion biopsy as a means of detecting clinically significant cancer as well as a potential
indicator for avoiding repeat biopsies. We performed a retrospective study of 374 men seen between
12/2012 and 06/2015. All patients underwent pre-biopsy mpMRI to identify regions of interest (ROIs) within
the prostate and each was assigned an MRI suspicion score. All patients then underwent a 12-core standard
trans-rectal mapping biopsy, and all patients with ROIs identified on mpMRI underwent MRI-US fusion
targeted biopsy. We defined cancer as any Gleason score ≥ 6, and we defined clinically significant cancer
as Gleason score ≥ 3+4. Statistical analysis was performed using chi squared, Fisher’s exact, student’s ttest, one-way ANOVA, and multivariate logistic regression. All test results were considered statistically
significant if p < 0.05. 143 patients were included in our analysis. Overall cancer detection rate was 42.66%,
and the clinically significant cancer detection rate was 27.27%. For standard 12-core mapping biopsy, the
cancer detection rate was 34.97%, and the clinically significant cancer detection rate was 18.18%. For men
who underwent targeted biopsies, the cancer detection rate of the targeted biopsies was 40.5%, and the
clinically significant cancer detection rate was 27.27%. In total, 21.50% of patients were upgraded by
inclusion of targeted biopsy. For the 72 patients with no cancer on targeted biopsy, only 2 were found to
have clinically significant cancer on mapping biopsy. A total of 213 ROIs were identified following mpMRI.
Cancer was found in 32.86% of the ROIs and clinically significant cancer was found in 22.54%. For the 22
patients with no target identified on MRI, none were found to have clinically significant cancer. Age, PSA,
MRI suspicion score, and PSA density were correlated with clinically significant. Anterior location of ROI was
significantly correlated with presence of cancer and higher grade cancer, particularly on targeted biopsy. For
clinically significant cancer detected on targeted biopsy, multivariate logistic regression revealed that the
only significant independent predictor of disease was the presence of an anteriorly located ROI on mpMRI
(OR 4.50, p < 0.01). In men with one or more previous negative biopsies and continued suspicion for
prostate cancer, mpMRI and MRI-US fusion targeted biopsy provide greater detection rate of clinically
significant disease compared to standard 12-core TRUS biopsy. Men with negative MRI findings may be
able to avoid or delay biopsy. Patients with high MRI suspicion score lesions and those with anterior lesions
are at increased risk for significant disease and should be treated with the necessary diligence.
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Introduction
Prostate Cancer
Prostate cancer is the most commonly diagnosed cancer in males in the United
States, with an estimated 181,000 new cases and 26,000 deaths in 2016.
Currently, the estimated lifetime risk of developing prostate cancer is
approximately one in seven 1. Annual rates of prostate cancer detection have
varied over the years. With the advent of PSA testing in the late 1980s, the
prostate cancer incidence rose dramatically, peaking in the early 1990s 2. Rates
of detection have since declined as the focus has shifted away from widespread
PSA screening in order to minimize over-detection of clinically insignificant
tumors 3. Meanwhile, rates of death from prostate cancer have declined steadily.
Currently, lifetime risk of death from prostate cancer is less than 3%, and the 5year survival rate for a new diagnosis of prostate cancer is greater than 99%.
Furthermore, the majority of prostate cancer deaths occur after the age of 75 1,3.
Though prostate cancer incidence has fluctuated over the past few
decades as screening guidelines and practices have changed, the true
prevalence of the disease remains difficult to measure. Prostate cancer is rarely
diagnosed as a result of clinical symptoms, with physicians relying on screening
exams and subsequent biopsies to drive the detection of the disease. This is
illustrated well in studies that compared histological examination of autopsy
specimens from men who died with no clinical evidence of prostate disease,
where the prevalence of malignancy is much higher than the corresponding ageadjusted incidence 4. A recent systematic review of autopsy studies spanning the
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1940s to the 2010s demonstrated varying prevalence of prostate cancer. Across
different age groups, cancer prevalence on autopsy ranged from 0% for patients
younger than 30 years old to more than 70% for patients greater than 70 years
old 5.

Risk Factors
Several risk factors have been identified that are associated with being
diagnosed with prostate cancer. The three primary risk factors associated with
the disease are age, race or ethnicity, and family history of the disease 6. Age
has the strongest association with the development of prostate cancer and has
been identified as a possible predictive factor, with an odds ratio of 1.71 per
decade identified by investigators in the systematic review of autopsy studies 5.
Race has been identified as a significant prostate cancer risk factor, with Black or
African-American men at a 1.6 times higher risk of diagnosis and a 2.5 times
higher risk of death than Caucasian men. African-American and Jamaican men
have been shown to have the highest rates of prostate cancer, while Asian men
have a lower rate than that of Caucasians. Interestingly, minority groups such as
Asians, Hispanics, and Native Americans have lower rates of disease than White
Americans, but are thought to be at higher risk as they are more assimilated into
American society. Investigations into possible environmental drivers of racial
disparity such as diet and obesity rates have not yielded convincing results,
though literacy and education have been correlated with increased stage at
presentation and greater risk of prostate cancer death, respectively 6.
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Finally, prostate cancer has been known to demonstrate clustering within
families, with 10-15% of patients having at least one other family member
afflicted by the disease. Studies have demonstrated at least a two-fold increase
in risk in patients with one affected first degree relative such as a father or
brother 7. A Swedish study from 2010 analyzed over 3.9 million men and
included over 25,000 cases of prostate cancer. Hazard ratios were reported for
men with increasing number of family members affected by the disease. The
hazard ratios were lowest at 1.8 for men with a father diagnosed later in his life
and highest at 23 for men with three affected brothers diagnosed at a younger
age. Generally, hazard ratios increased with decreasing age at diagnosis of the
affected family members 8. Another large Scandinavian study examined cohorts
of twin pairs, concluding that prostate cancer demonstrated higher concordance
for cancer in identical twins than breast or colorectal cancer and suggesting that
up to 42% of prostate cancer risk can be attributed to heritable factors 9.
Genomic studies have revealed the complex nature of prostate cancer genetics,
with many SNPs identified as independently associated with the disease 10.
Other studies have emphasized the importance of BRCA1 and BRCA2 mutations
on prostate cancer diagnosis and mortality, as well as increased risk related to
HOXB13 germline mutations 11,12.

Screening for Prostate Cancer
While prostate cancer survival rates are excellent overall, there is a significant
discrepancy between five-year survival rates for patients diagnosed with locally
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or regionally contained disease and disease with distant metastases at the time
of diagnosis. With the presence of distant metastases at the time of diagnosis,
the five-year survival rate falls from 100% to a mere 28.2% 13. It is clear that
prostate cancer is a disease with a broad range of lethality, considering the
disparity in mortality between locally contained and disseminated disease, as
well as the prevalence of incidental disease found on autopsy. In response,
physicians have attempted to optimize population screening guidelines in order
to prevent life-threatening cases while avoiding overdiagnosis of nonlethal
disease.
The oldest screening test for prostate cancer is the digital rectal
examination, or DRE. It has been performed to detect nodules, asymmetry, or
induration that may suggest the presence of tumors in the posterior and lateral
aspects of the gland. Unfortunately, not all tumors arise in these locations 14.
Furthermore, the effectiveness of the DRE as an exam has been called into
question given the subjective nature of the test and the fair, but not great level of
interrater agreement 15. A metaanalysis of DRE performance suggested a
sensitivity of 59%, specificity of 94%, and a positive predictive value of only 28%
16

.
Screening for prostate cancer with PSA testing began in the late 1980s,

and in 1992 the American Cancer Society recommended annual screening with
DRE and PSA for men over the age of 50 17. PSA is a glycoprotein produced
specifically by prostate epithelial cells and has a half life of 2.2 days. Early
analysis of PSA found a correlation between PSA levels and increasing clinical
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stage, as well as cancer volume. Investigators noted, however the wide range of
PSA levels in patients with locally confined disease and the elevation of PSA
associated with benign prostatic hypertrophy. PSA was identified as an excellent
tool for surveillance and detection of recurrent disease following surgical
intervention or radiation therapy 18. Other studies have concluded that PSA
elevations can precede detection of prostate cancer by five to ten years 19.
However, reliability of PSA screening has been a topic of significant debate. PSA
can be affected by a range of benign conditions, including ejaculation, acute
urinary retention, inflammation or prostatitis, digital rectal exam, transrectal
ultransonography, or prostate biopsy 20–22. Medications, especially five-alpha
reductase inhibitors such as finasteride and dutasteride, may reduce PSA levels
by as much as 50% 23,24.
Evaluating the effectiveness of PSA has been challenging for a number of
reasons. First, most men with normal PSA values do not undergo confirmatory
biopsy, leading to a verification bias that overestimates sensitivity and
underestimates specificity 25. Furthermore, PSA is usually compared to results of
prostate biopsy, which in itself is an imperfect and evolving test 26. Nevertheless,
the American Cancer Society performed a systematic review in 2009 to evaluate
PSA screening. The investigators estimated that PSA screening with a cutoff of
4.0 ng/mL led to a sensitivity of 21 percent for detecting any cancer and 51
percent for detecting high grade disease, as well as a specificity of 91% 27. The
positive predictive value of PSA screening has been best studied, with a
multicenter clinical trial of over 6,000 men finding a positive predictive value of
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32% for PSA over 4.0 ng/mL, but only 25% for men with PSA between 4.0 and
10.0 ng/mL 28. Another large trial, the Prostate Cancer Prevention Trial,
estimated negative predictive value of PSA under 4.0 ng/mL to be 85% after
studying biopsies of men with normal PSA values 29.
Multiple strategies have been proposed to attempt to increase the
accuracy of PSA testing to improve detection of high risk disease. These include
age- and race-specific cutoff values, measuring PSA values over time (PSA
velocity) or with respect to prostate size (PSA density), and relative levels of free
versus complexed PSA 30. Unfortunately, none of these methods has significantly
improved the diagnostic accuracy of PSA 31–33. In 2012, after performing a review
of the evidence regarding the efficacy of PSA screening, the USPSTF published
new prostate cancer screening guidelines, giving PSA screening a D rating and
recommending against its use 34,35. This recommendation was met with
controversy, as some groups felt as though the USPSTF underestimated the
benefits of screening while overstating the harms 36. The American Urological
Association subsequently published a new recommendation encouraging
providers to engage in shared decision making with patients and to explain the
risks and benefits of PSA screening, especially to those at higher risk, such as
African American men, and men with a life expectancy greater than 10 years 37.

Diagnosis of Prostate Cancer
Despite the controversy over screening and early detection of prostate cancer,
many men continue to be referred to a urologist for evaluation following an
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elevated PSA or abnormal DRE. Diagnosis of prostate cancer is performed
through clinical examination combined with histological assessment of tissue
obtained via prostate biopsy. Prostate biopsy is primarily performed via one of
two anatomical approaches. The first and most common approach is the
transrectal ultrasonography (TRUS)-guided prostate biopsy, a technique that was
developed in the late 1980 and was formalized with the introduction of the TRUSguided systematic sextant biopsy protocol by Hodge in 1989 14. This procedure is
commonly done in the office setting with local anesthesia, and involves a
transrectal ultrasound probe through which spring-loaded needles may be
inserted and guided into the different regions of the prostate 38. These regions
include the anterior fibromuscular stroma, transition zone (TZ), central zone (CZ),
periurethral zone, and peripheral zone (PZ). TRUS-guided biopsy assists the
operator in obtaining samples from various regions of the prostate and at times
the seminal vesicles, which are located posteriorly at the base of the gland.
The number and distribution of sample cores taken has evolved over time.
The original scheme included six cores – one from the base, mid, and apex of
the gland on each side. This sextant protocol improved upon the previous
standard, where samples were digitally directed 39. Subsequent pathological
studies of radical prostatectomy specimens demonstrated that the majority of
disease arises in the posterolateral PZ, and modifications to the sextant scheme
were introduced to focus on sampling the lateral areas of the gland 40. The
current method endorsed by the American Urological Association is the extended
12-core systematic biopsy that includes apical and far-lateral cores 41. A
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saturation biopsy with an increase in the number of cores to 18 or more on initial
biopsy has not demonstrated the same benefit as the increase from six to 12,
though studies have shown an decrease in clinically significant cancer detected
on repeat biopsy after initial saturation biopsy 42.
The transperineal prostate biopsy has typically been used as an
alternative approach for patients who are unable to undergo a transrectal
procedure. A 2008 prospective randomized trial compared the transperineal and
transrectal approache and found no significant difference in cancer detection
rates and complications between the two approaches 43. The authors concluded
that the transrectal approach is preferred as it can be performed with local
anesthesia, as opposed to the transperineal approach, which requires spinal or
more generalized anesthesia. Recent reviews of the evidence, however, have
argued for a larger role for transperineal biopsy, citing improved sampling of the
anterior and apical sides of the prostate with lower false negative rate and
reduced risk of underestimating disease grade 44. The authors argue that
transperineal biopsy, though more costly than transrectal biopsy, may be
especially useful for patients with a previous negative transrectal biopsy.
With both types of biopsy method, there are risks and complications of the
procedure. Prostate biopsy is generally well tolerated and considered a safe
procedure, with less than 1% of patients suffering serious complications requiring
hospitalization. The most common post-biopsy complications include infection,
ranging from UTI and low-grade fever to sepsis, and bleeding. These risks are
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mitigated through prophylactic antibiotic administration and periprocedural
management of the minor complications that may arise 14.

Prostate Cancer Clinical Staging
The clinical staging of prostate cancer takes into account multiple pretreatment
parameters to predict the extent of the disease. This allows for an assessment of
prognosis and helps providers and patients to select the best option for initial
management. The parameters that are considered for clinical staging are DRE,
PSA and related blood tests, tissue histology on needle biopsy, and results of
imaging 14. The current system of clinical staging is based on the tumor, node,
metastasis (TNM) classification system first adopted by the American Joint
Committee on Cancer (AJCC) in 1975 and modified for prostate cancer in 1992
45

. The latest version from the AJCC combines TNM stage with PSA value and

histological grade to categorize patients into one of four prognostic groups 46.
Histologic grading of tissue obtained through prostate biopsy is performed
using the Gleason grading system 47. The system involves taking the sum of the
predominant grade at low-power magnification and the grade of the second most
common pattern in the sample to yield a score from 2 to 10. More recent
research and discussion regarding Gleason scores has focused on the effect that
tertiary Gleason patterns may have, especially when they are grade 5.
Furthermore, Gleason 6 scores have been identified to be of low risk, and
stratification between Gleason 3+4 and 4+3 tumors has been suggested 14.
Higher Gleason score is associated with worse prognosis, but other factors such
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as PSA level, number of positive cores, percentage of positive cores, and
presence of perineural invasion are taken into account when performing riskstratification 48. Risk nomograms that predict pre-operative extent of disease
have been developed from institutional experience, and other validated
classification schemes such as the Cancer of the Prostate Risk Assesment
(CAPRA) score have been developed to help predict longer term outcomes
following treatment 49,50.

Initial Management of Prostate Cancer
Following prostate cancer tissue diagnosis from biopsy, initial staging should be
completed for patients with Gleason 7 or greater with a radionuclide bone scan
and abdominal-pelvic CT or MRI scan in order to best direct initial management.
Depending on the prognostic risk group that the patient falls into, there are many
different options available for initial disease management. The most conservative
of these are watchful waiting and active surveillance. Watchful waiting typically
refers to the observation of a patient who will develop metastases and then
require palliative care, while active surveillance, also known as expectant
management, allows for the delay of primary treatment until there is biochemical
or histological evidence of cancer progression. Active surveillance is typically
reserved for patients with low-risk disease (Gleason score < 6, PSA < 10 and
clinical stage < T2a), though it may have some benefit for patients with Gleason
7 (3 + 4) tumors 51. It has typically been used for men with a life expectancy < 10
years, although rates of active surveillance are increasing and include younger
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men 52. Because delaying treatment may lead to cancer progression and loss of
curative potential, these initial management decisions must be carefully
considered 53. Investigators have constructed statistical models to predict which
tumors are likely to progress and which are likely to remain indolent. The Epstein
criteria, established in 1994, identified factors such as tumor volume < 0.2 cm3
and Gleason score < 7 that predict the presence of “clinically insignificant”
disease, as evaluated on pathological staging 54. These criteria were updated in
1998 to include a free/total PSA ratio (0.15 or greater) and other favorable needle
biopsy findings (fewer than three cores involved and < 50% of any one core) to
attain a positive predictive value of 95% and a negative predictive value of 77.2%
for “insignificant” tumors 55.
While active surveillance may be the optimal choice for patients with low
risk disease, patients with clinically significant tumors require interventional
treatment. The primary categories of established treatments include radiation
therapy and radical prostatectomy. Hormone therapy with androgen deprivation
is most often used in conjunction with radiation therapy as a primary treatment
option. Androgen deprivation therapy (ADT) is generally recommended for
unfavorable intermediate-risk, localized high-risk, and locally advanced prostate
cancer based on results of clinical trials involving patients with locally advanced
prostate cancer 56. ADT has also been employed in the salvage setting, and was
previously used for primary therapy as a palliative care for men with shorter life
expectancy who did not wish to seek more aggressive treatment 14. However, a
recent trial comparing 15,000 men who received ADT with no other treatment
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showed no mortality benefit 57. Meanwhile, the risks of associated with ADT have
been well described and include increased risk of diabetes and cardiovascular
disease 58. ADT is still being evaluated in clinical trials as an adjunct to salvage
radiotherapy.
Radiation therapy and radical prostatectomy are typically considered the
two primary options to provide biochemical control over prostate cancer. There
are two main categories of radiotherapy, external beam radiation therapy, and
brachytherapy. External beam radiation therapy includes intensity-modulated
radiation therapy (IMRT), stereotactic body radiation therapy, and heavy-particle
radiotherapy. IMRT is a sophisticated form of 3D conformal radiotherapy that
utilizes computers to focus the photon radiation dose to the prostate in an effort
to deliver maximum effect while minimizing radiation of adjacent structures 59.
Stereotactic body radiation therapy, also known as Cyberknife, delivers higher
doses of radiation over much smaller periods of time, a process known as
hyperfractionation. The cost is less than that of IMRT and initial results show
similar treatment efficacy, though longer term results are not yet available 60.
Heavy-particle radiotherapy utilizes proton or neutron beams and has the
potential for even more focused radiation delivery, though at increased cost 14.
Early results suggest that heavy-particle radiotherapy is comparable to IMRT in
clinical and quality of life measures 61,62. Brachytherapy involves the implantation
of radioactive seeds or needles into the prostate gland to deliver a high dose of
radiation and has been shown to be effective in patients with low- and
intermediate-risk localized disease 63. While radiotherapy can deliver targeted
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treatment, side effects including gastrointestinal and urinary morbidity and
erectile dysfunction 61.
Radical prostatectomy was the first treatment developed for prostate
cancer, with earliest reports dating back to Kuchler in 1866 and Young in 1905 at
Johns Hopkins 14. Despite its complexity and considerable risks of side effects,
the procedure remains the gold standard in attempting a curative intervention.
Radical prostatectomy may be performed through one of a few different
approaches, including perineal, open retropubic, laparoscopic, and robotic. There
has been debate regarding the optimal approach, especially in context of the rise
in popularity of robotic prostatectomy since its introduction in 2000 with the da
Vinci Surgical System. Studies comparing the robotic approach to the open
retropubic approach have concluded that the two methods are comparable on
functional and oncologic outcomes, while other studies have demonstrated more
favorable rates of side effects for each 64–66. The primary advantage of the radical
prostatectomy over other forms of treatment is its potential for cure with minimal
collateral damage when correctly and skillfully performed 67. Additionally, more
accurate tumor staging may be performed upon pathological examination of the
surgical specimen, and treatment failure is more easily identified, allowing for
timely initiation of salvage therapy 14. Disadvantages of radical prostatectomy
include the necessary hospitalization and postoperative recovery, possibility of
incomplete resection, and risk of erectile dysfunction and urinary incontinence.
The “trifecta” of priorities for radical prostatectomy include cancer control,
preservation of continence, and preservation of potency 68. Generally, younger,
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healthier men with life expectancy of at least ten years are the best candidates
for radical prostatectomy.

Importance of Representative Tissue Sampling
The choice of optimal therapy depends greatly upon the patient’s risk group and
life expectancy 14. In turn, the risk group is heavily influenced by clinical stage. A
continued concern with current prostate biopsy methods is the risk for nonrepresentative tissue sampling. Patients who are categorized as low-risk
following prostate biopsy that demonstrated Gleason 6 disease may enter an
active surveillance protocol only to find that higher grade disease was present in
their prostate but did not happen to be detected by one of the 12 cores. In a 2012
systematic review, investigators found that 42% of men who would have fallen
into the D’Amico low-risk group were found to have an increase in Gleason score
following rebiopsy or pathological analysis of radical prostatectomy specimen.
When using Epstein criteria, an increase in risk group was found in 34% of
patients 69. A 2010 study found that 47% of active surveillance patients
undergoing radical prostatectomy were found to have Gleason 7 or greater
disease 70. In a recent Swedish study of men with very low risk prostate cancer
(T1c, PSA concentration less than 10 ng/ml, PSA density < 0.15 ng/ml2, Gleason
6 in up to 4 positive biopsy cores with a total biopsy cancer length of ≤ 8 mm)
who underwent radical prostatectomy, 34% had upgrading to stage pT3 or
Gleason 7 or higher 71. Another study that used modified Epstein criteria (PSA <
10 ng/ml, positive biopsy cores ≤ 3, and maximum involvement of any single core
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≤ 50%) found that in men who were considering active surveillance and had a
rebiopsy within three months of initial biopsy, 27% were upgraded or upstaged
on repeat biopsy. These men were also significantly less likely to have organ
confined disease or Gleason 6 or lower disease upon prostatectomy 72. On the
other side, we would prefer to detect fewer indolent tumors that are truly clinically
insignificant in order to avoid overdiagnosis and the accompanying increases in
costs and morbidity.

Use of MRI in Prostate Cancer Diagnosis
As discussed above, introduction of TRUS significantly increased the cancer
detection rate of transrectal prostate biopsy 39. However, TRUS imaging has
been unable to reliably identify and localize tumors within the prostate 73. In fact,
TRUS was shown to be no better than DRE in predicting disease outcome 74.
Another imaging modality, MRI, has also long been investigated for its ability to
assist with clinical staging. For many years, however, MRI did not demonstrate
consistency in localizing tumors within the gland 75. However, recent advances in
MRI imaging have allowed for reevaluation of the utility of MRI in prostate cancer
diagnosis. Multiparametric MRI (mpMRI) is a type of study that involves multiple
MRI sequences including T2-weighted imaging, diffusion weighted imaging, and
perfusion imaging and presents the individual sequences in an integrated
manner 76. Studies have demonstrated that mpMRI is the most accurate
noninvasive technique to localize prostate cancer and can assist in risk
stratification 77. A study by Rosenkrantz et al evaluated the ability of mpMRI to
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localize index lesions later identified on pathological specimen. Across six
different MRI readers, the investigators found an average sensitivity of 60.2%
with positive predictive value of 65.3% for an exact match, and an average
sensitivity of 75.9% with positive predictive value of 82.6% for an approximate
match 78. MpMRI has also been shown to have high negative predictive value for
the presence of extracapsular extension in low risk patients and high positive
predictive value for local disease advancement in high risk patients 79. With the
success of mpMRI in identifying prostate lesions, scoring systems have been
adopted, including a three or five point Likert scale based on impression and the
PI-RADS classification system based on fixed criteria 80,81. These MRI suspicion
scores have been demonstrated to be strongly correlated with higher grade
disease, and are thought to be a clinically useful parameter to help characterize
prostate cancer 82,83.

MRI-Guided Biopsy Techniques
With better localization of tumors in the gland through mpMRI, new biopsy
techniques have been developed to attempt to target the suspicious region of
interest (ROI) identified on imaging studies. These MRI-guided targeted TRUS
biopsies include visual estimation or cognitive fusion biopsy, in-bore biopsy, and
software co-registered fusion biopsy. Visual estimation, also known as MRI
cognitive fusion, is the least costly MRI-guided biopsy technique but lacks real
time feedback and carries significant interoperator variability and learning curve.
Some studies have found a lower cancer detection rate with visual estimation
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than systematic or template biopsy, while others have found significantly higher
rates of cancer detection with MRI-guided visual estimation 76. In-bore MRIguided biopsy involves performing prostate biopsy while the patient remains
inside the MRI unit. Due to the vast increase in cost compared to TRUS-guided
biopsy, in-bore MRI-guided biopsy has generally been reserved for patients who
have had a prior negative biopsy with continued suspicion for prostate
malignancy. Many studies have demonstrated a cancer detection rate above
40% with 80-90% of tumors being clinically significant 84.
Software co-registered MRI-guided biopsy is typically achieved through
co-registration of the MRI image with a series of TRUS images that are taken at
the time of the biopsy. The software then constructs a three-dimensional
rendering of the prostate gland and aligns the biopsy with the co-registered
image of the ROIs seen on mpMRI. These MRI-US fusion biopsy devices are
manufactured by various companies and involve a high up-front investment as
well as a learning curve for its utilization 76. MRI-US fusion biopsy has
demonstrated to be more likely to detect cancer than standard 12-core TRUS
biopsy, detect more cancer per core, upgrade Gleason scores when compared to
12-core biopsy, and detect more high-risk prostate cancer while detecting less
low-risk prostate cancer 85–88. In a recent meta-analysis of studies evaluating
MRI-guided biopsy techniques, investigators did not find a difference in overall
cancer detection rate, but did observe a higher rate of detection of clinically
significant disease and a lower rate of detection of clinically insignificant disease
89

.
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Men with Prior Negative Biopsy
A particularly challenging subpopulation of prostate cancer patients are those
who present with a persistently elevated PSA and suspicion of prostate cancer
despite having had one or more prior negative prostate biopsies. Following a
negative prostate biopsy, the information provided by serial serum PSA and PSA
kinetics is limited, and many patients ultimately undergo repeated biopsy
procedures in search of a histological answer for persistently elevated serum
PSA. These repeat biopsies may be unnecessary, and, furthermore, may lead to
overdiagnosis of clinically insignificant prostate cancer and subsequent
overtreatment. The risk of missing clinically significant disease, especially in the
context of the imperfect sampling methods of standard TRUS-guided 12-core
biopsy, has prompted some men to receive as many as 10 prostate biopsies 90.
For patients with at least one negative prostate biopsy, previous studies
have described cancer detection rates on subsequent biopsies. Overall, cancer
detection rates on repeat biopsies are significantly lower than on an initial biopsy
with the standard TRUS-guided 12-core approach 91. In a retrospective study of
2,500 men who underwent up to 10 repeat biopsies, Roehl et al. found that the
serial cancer detection rates were 29%, 17%, 14%, 11%, 9% and 7%, on the first
six successive biopsies 90. Low diagnostic yield was also found when men with
prior negative biopsies underwent saturation biopsy to attempt to detect
significant disease 92. Contrarily, a recent study found a CDR of 25% on the
fourth biopsy in a cohort of 255 men with initial negative biopsy 93.
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With the improvements made in prostate imaging through mpMRI and the
development of new MRI-guided prostate biopsy techniques, patients with prior
negative biopsies may benefit from these advances. Many studies have
demonstrated the utility of mpMRI and MRI-guided biopsy for these patients.
Cancer detection rates superior to standard TRUS biopsy have been described,
as well as a greater proportion of clinically significant disease among detected
cancers 94,95. Another recent study found an increased cancer detection rate as
well as improved risk stratification with repeat biopsies using mpMRI and MRI-US
fusion biopsy 96. This value of mpMRI has also been well documented, and MRI
suspicion scores have been shown to be a strong predictor of significant cancer
detection on subsequent MRI-guided biopsy 97–99. Furthermore, a systematic
review demonstrated that in men with at least one negative prior biopsy, the twothirds (328 of 479) with an MRI abnormality led to a positive biopsy rate of 70%
(229 of 328) when rebiopsied using an MRI-guided procedure 100. This has led
some investigators to suggest using mpMRI as a screening tool to help reduce
the number of unnecessary biopsies in men with prior negative biopsy results 101.
In this paper, we evaluate mpMRI and MRI-US fusion biopsy as a means of
detecting clinically significant cancer as well as a potential indicator for avoiding
repeat biopsies.
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Methods
We performed a retrospective study utilizing data collected from clinical
encounters between 12/2012 and 06/2015. During this period, 374 men with an
indication for prostate biopsy presented to our institution. All patients underwent
pre-biopsy mpMRI which was subsequently read by experienced radiologists
who identified any region of interest (ROI) and assigned a MRI suspicion score
based on either a 3-point Likert scale or the PI-RADS classification system. All
patients then underwent a 12-core standard trans-rectal mapping biopsy, and all
patients with ROIs identified on mpMRI underwent MRI-US fusion targeted
biopsy of those lesions with at least one biopsy core taken per target. All targeted
biopsies were performed using the Artemis/Pro-Fuse™ system (Eigen, Grass
Valley, California).
Other members of the prostate cancer research group led by Dr. Preston
Sprenkle created a secure database of patient information stored on a secure
Yale server. The data entered in the database was retrospectively encoded from
information found in the patient electronic medical record, including procedure
notes and pathology reports. This data was then downloaded and transferred in
deidentified form.
From among this set, only men with at least one previous biopsy and no
diagnosis of prostate cancer were included in our analysis. Variables included in
the data analysis consist of the following: patient age, serum PSA level at time of
biopsy, number of previous biopsies, prostate volume measured on MRI,
prostate volume measured on TRUS, MRI result, MRI suspicion scores for each
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ROI, location for each ROI, clinical stage, and information for each biopsy core
taken including location, primary Gleason pattern, secondary Gleason pattern,
percent of core occupied by cancer, length of cancer in each core, and qualitative
description of histology. Maximum Gleason score was then assigned on a perpatient basis based on the highest Gleason score found on any mapping biopsy
or targeted biopsy core.
The author proceeded to process this data set and encode it to allow for
data analysis. PSA density was calculated twice by dividing serum PSA level by
prostate volume on TRUS and MRI. Location of ROI was encoded into four
variables differentiating between left and right; anterior and postieror; base, midgland, and apex; and McNeal zone of the gland. Because some patients had MRI
suspicion score reported on a three point Likert scale while others were graded
according to PI-RADS, we combined the MRI suspicion score into a single
variable by translating PI-RADS scores to the three point Likert scale. Patients
were then evaluated for the detection of cancer through each biopsy method. We
defined cancer as any Gleason score ≥ 6, and we defined clinically significant
cancer as Gleason score ≥ 3+4.
Statistical analysis was performed by the author using Stata 13 software
(Statacorp, College Station, Texas). Summary statistics included mean, standard
deviation, median, minimum, and maximum. Comparative statistics between
groups of patients were performed using chi squared, Fisher’s exact, student’s ttest, and one-way ANOVA. Multivariate logistic regression was performed to
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evaluate predictive qualities of patient characteristics. All test results were
considered statistically significant if p < 0.05.
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Results
Upon analysis of the available data, 143 of the 374 patients met inclusion criteria.
Analysis was performed at the patient level and the ROI level.

Patient Characteristics
The overall mean age of men included was 64.1 years with a minimum of 47
years and a maximum of 82 years. Mean PSA at time of biopsy was 11.59 ng/mL
with a minimum of 0.4 ng/mL and a maximum of 96.90 ng/mL. On average, men
in this cohort had received 1.8 previous negative biopsies with the greatest
number being 5. Mean MRI-measured prostate volume was 68.52 mL (16.5 –
309) and mean TRUS-measured prostate volume was 67.67 mL (8.81 – 243).
Mean PSA density was 0.20 ng/mL2 (0.01 – 1.82) when calculated with TRUS
volume and 0.21 ng/mL2 (0.01 – 1.45) when calculated with MRI volume. Of the
143 men, 139 (97.2%) successfully completed the pre-biopsy multiparametric
MRI, while the remaining 4 were unable to tolerate a complete exam.

MRI Results
Twenty-two patients (15.38%) had no suspicious lesions seen on MRI. Two of
the patients with an incomplete exam did not have suspicious lesions reported
during the part of the exam that was completed. Of the patients with suspicious
lesions identified on MRI, 24 patients (16.78%) had only low suspicion lesions,
40 patients (27.97%) had at least one moderate suspicion lesion with no high
suspicion lesions, and 55 patients (38.46%) had one or more high suspicion
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lesion. Of patients with ROIs on mpMRI, 61 (50.41%) had at least one anteriorly
located ROI.
A total of 213 ROIs were identified following mpMRI. Of these 213,
47.89% (102) were located on the left lobe of the gland and 51.64% (110) were
located on the right lobe of the gland. There was no left vs right sided information
for 1 ROI. Between anterior and posterior location within the gland, 33.33% (71)
were located in the anterior portion while 64.79% (138) were located in the
posterior portion of the gland. There was no anterior vs posterior information for 4
of the ROIs. Among base, mid, and apex regions of the gland, 24.41% (52) were
located in the base of the gland, 49.30% (105) were located mid-gland, and
25.35% (54) were located in the apex of the gland. There was no information in
this dimension for 2 of the ROIs. Regarding McNeal zone of the prostate gland,
75.12% (160) were located in the peripheral zone, 18.78% (40) were located in
the central or transitional zone, 3.29% (7) were located in the anterior stroma,
and 0.47% (1) were located in the seminal vesicles. There was no McNeal zone
information for 5 of the ROIs. The MRI suspicion scores of these ROIs were
distributed as follows: 20.66 % (44) were low suspicion, 37.55% (80) were
moderate suspicion, and 39.44% (84) were high suspicion. There was no MRI
suspicion score reported for 5 of the ROIs.

Overall Biopsy Results
Including both 12-core mapping biopsy and targeted biopsy, the overall cancer
detection rate was 42.66% (61 of 143 patients), and the clinically significant
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cancer detection rate was 27.27% (39 of 143 patients). Of these men with cancer
detected on mapping biopsy or targeted biopsy, 36.07% (22) had Gleason 3+3
disease, 29.5% (18) had Gleason 3+4 disease, and 34.43% (21) had Gleason
4+3 or greater disease. Between men with and without cancer found on mapping
biopsy or targeted biopsy, there was no statistically significant difference in mean
age (64.71 vs 63.68, p = 0.39), PSA (13.33 vs 10.29, p = 0.09), or number of
previous biopsies (1.74 vs 1.89, p = 0.43). There was a difference in mean
prostate volume as measured on MRI (50.62 vs 82.0, p < 0.01) and mean PSA
density (0.29 vs 0.14, p < 0.01). Between men with and without clinically
significant cancer found on mapping biopsy or targeted biopsy, there was no
significant difference in mean number of previous biopsies (1.85 vs 1.82, p =
0.89). There was a statistically significant difference in mean age (66.02 vs 63.4,
p = 0.05), PSA (15.61 vs 10.08, p < 0.01), prostate volume on MRI (51.71 vs
74.88, p < 0.01), and PSA density (0.34 vs 0.16, p < 0.01). Having an anteriorly
located ROI was significantly correlated with detection of cancer (65.57% vs
30.00%, p < 0.01) and detection of clinically significant cancer (44.26% vs
10.00%, p < 0.01).

Mapping Biopsy Results
For standard 12-core mapping biopsy, the overall cancer detection rate was
34.97% (50 of 143 patients), and the clinically significant cancer detection rate
was 18.18% (26 of 143 patients). Of the men with cancer detected on mapping
biopsy, 48.0% (24) had Gleason 3+3 disease, 22.0% (11) had Gleason 3+4
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disease, and 30.0% (15) had Gleason 4+3 or greater disease. Between men with
and without cancer found on mapping biopsy, there was no statistically significant
difference in mean age (65.04 vs 63.6, p = 0.24) or number of previous biopsies
(1.68 vs 1.90, p = 0.26). There was a significant difference in mean PSA (14.04
vs 10.27, p = 0.04), prostate volume on MRI (50.62 vs 78.24, p < 0.01), and PSA
density (0.31 vs 0.15, p < 0.01). Between men with and without clinically
significant cancer found on mapping biopsy, there was no significant difference in
mean number of previous biopsies (1.92 vs 1.80, p = 0.63). There was a
statistically significant difference in mean age (67.77 vs 63.28, p < 0.01), PSA
(18.43 vs 10.07, p < 0.01), prostate volume on MRI (50.82 vs 72.49, p = 0.03),
and PSA density (0.41 vs 0.16, p < 0.01). For mapping biopsy, having an
anteriorly located ROI was significantly correlated with detection of cancer
(49.18% vs 28.33%, p = 0.02) but not correlated with detection of clinically
significant cancer (26.23% vs 16.67%, p = 0.20).

Targeted Biopsy Results
For men who underwent targeted biopsies, the overall cancer detection rate of
the targeted biopsies was 40.5% (49 of 121 patients), and the clinically significant
cancer detection rate was 27.27% (33 of 121 patients). Of the men with cancer
detected on targeted biopsy, 32.65% (16) had Gleason 3+3 disease, 28.57% (14)
had Gleason 3+4 disease, and 38.78% (19) had Gleason 4+3 or greater disease.
Between men with and without cancer found on targeted biopsy, there was no
statistically significant difference in mean age (65.51 vs 63.51, p = 0.14) or
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number of previous biopsies (1.88 vs 1.82, p = 0.79). There was a difference in
mean PSA (14.00 vs 10.39, p = 0.05), prostate volume on MRI (51.84 vs 76.13, p
< 0.01), and PSA density (0.31 vs 0.16, p < 0.01). Between men with and without
clinically significant cancer found on targeted biopsy, there was again no
significant difference in mean age (66.16 vs 63.61, p = 0.09) and number of
previous biopsies (1.88 vs 1.83, p = 0.84). There was a statistically significant
difference in mean PSA (16.87 vs 10.20, p < 0.01) prostate volume on MRI
(52.03 vs 71.64, p = 0.02), and PSA density (0.35 vs 0.17, p < 0.01). For targeted
biopsy, having an anteriorly located ROI was significantly correlated with
detection of cancer (59.02% vs 21.67%, p < 0.01) and detection of clinically
significant cancer (42.62% vs 11.67%, p < 0.01).

Mapping Biopsy vs Targeted Biopsy
In comparing the results of mapping biopsy and targeted biopsy for each patient,
11 of the 93 patients (11.83%) who did not cancer found on mapping biopsy were
found to have cancer on targeted biopsy. Of these 11, 6 were Gleason 3+3, 3
were Gleason 3+4, and 2 were Gleason 4+3 or greater. Of the 24 patients who
were found to have Gleason 3+3 disease on mapping biopsy, 5 (20.83%) were
upgraded to Gleason 3+4 following targeted biopsy, and 3 (12.5%) were
upgraded to Gleason 4+3 or greater. Only 1 of the 11 patients (9.09%) with
Gleason 3+4 disease on mapping biopsy was found to have Gleason 4+3
disease on targeted biopsy. In total, 21.50% (20 of 93) of patients were upgraded
by inclusion of targeted biopsy. For the 72 patients found to have no cancer on
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targeted biopsy, only 9 (12.5%) were found to have cancer on mapping biopsy.
Seven of these were Gleason 3+3 disease, and the remaining 2 had Gleason
4+3 or greater disease. Sixteen patients were found to have Gleason 3+3
disease on targeted biopsy, and 4 of these 16 (25%) were found to have Gleason
3+4 disease and none were found to have Gleason 4+3 or greater disease. Of
the 14 patients with Gleason 3+4 disease on targeted biopsy, none were found to
have Gleason 4+3 or greater disease on mapping biopsy. For the 22 patients
with no target identified on MRI, 3 (13.64%) were found to have Gleason 3+3
disease on mapping biopsy, and none were found to have any clinically
significant cancer. Overall, 14 of 143 patients (9.79%) were upstaged in clinically
significant risk category when targeted biopsy was added to mapping biopsy,
while 6 (4.2%) were upstaged in clinically significant risk category when mapping
biopsy was added to targeted biopsy.

ROI-Level Results
Cancer was found in 32.86% (70 of 213) of the ROIs. Clinically significant cancer
was found in 22.54% (48 of 213) of the ROIs. Of the ROIs with cancer detected
on targeted biopsy, 31.43% (22) had Gleason 3+3 disease, 28.57% (20) had
Gleason 3+4 disease, and 40.00% (28) had Gleason 4+3 or greater disease.
There was a strong correlation between MRI suspicion scores and presence of
cancer, with cancer found in 47.62% of high suspicion ROIs, 26.25% of moderate
suspicion ROIs, and 13.64% of low suspicion ROIs (p < 0.01). This relationship
was also demonstrated for clinically significant cancer, with Gleason 3+4 or
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greater disease found in 38.10% of high suspicion ROIs, 15.00% of moderate
suspicion ROIs, and 6.82% of low suspicion ROIs. Between ROIs with and
without cancer found on targeted biopsy, there was no significant correlation in
location in terms of left vs right (p = 0.41) and base vs mid-gland vs apex (p =
0.47). There was a statistically significant correlation regarding anterior vs
posterior location (p < 0.01) and McNeal zone (p = 0.04). There was cancer
found in 50.70% of anterior ROIs compared to 23.19% of posterior ROIs.
Regarding McNeal zone, there was cancer found in 28.12% of ROIs in the
peripheral zone, 40.00% of ROIs in the central or transitional zone, 71.43% of
ROIs in the anterior stroma, and 0.00% of ROIs in the seminal vesicles. Between
ROIs with and without clinically significant cancer found on targeted biopsy, there
was again no correlation in terms of left vs right (p = 0.53) and base vs mid-gland
vs apex (p = 0.21). There was a statistically significant correlation regarding
anterior vs posterior location (p < 0.01) and McNeal zone (p < 0.01). There was
clinically significant cancer found in 38.03% of anterior ROIs compared to
15.22% of posterior ROIs. Regarding McNeal zone, there was cancer found in
18.75% of ROIs in the peripheral zone, 27.50 % of ROIs in the central or
transitional zone, 71.43% of ROIs in the anterior stroma, and 0.00% of ROIs in
the seminal vesicles.

Predicting Biopsy Results
As discussed above, multiple factors were correlated with presence of clinically
significant disease across biopsy methods in univariate analysis. Age, PSA, MRI

30
suspicion score, and PSA density were correlated with clinically significant
disease in both mapping biopsy and targeted biopsy conditions. Anterior location
of ROI was a particularly interesting factor, as it was significantly correlated with
presence of cancer and higher grade cancer, particularly on targeted biopsy. In
multivariate logistic regression with independent variables Age, PSA, PSA
density, prostate volume on MRI, number of previous biopsies, MRI suspicion
score, and presence of anteriorly located ROI, only high suspicion score (OR
5.36, p = 0.02) and PSA density (OR 1.09 per 0.01 ng/mL2, p = 0.03) were
significant independent predictors of clinically significant disease found on
mapping or targeted biopsy. Presence of an anteriorly located ROI approached
significance with odds ratio 2.56 (p = 0.07). For clinically significant cancer
detected on mapping biopsy, multivariate logistic regression demonstrated that
Age (OR 1.11, p = 0.03) and PSA density (OR 1.13 per 0.01 ng/mL2, p < 0.01)
were significant independent predictors of disease. For clinically significant
cancer detected on targeted biopsy, multivariate logistic regression revealed that
the only significant independent predictor of disease was the presence of an
anteriorly located ROI on mpMRI (OR 4.50, p < 0.01). High MRI suspicion score
approached statistical significance with OR 3.88 (p = 0.10). Interestingly, PSA
density was not a significant independent predictor of clinically significant disease
found on targeted biopsy (p = 0.57).
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Discussion
Patients who present with a persistently elevated PSA and one or more prior
negative prostate biopsies present a common management dilemma. Consensus
guidelines for rebiopsy have not been determined, and the optimal method of
rebiopsy continues to be investigated. An ideal approach would detect patients
with clinically significant prostate cancer while avoiding morbidity related to
excessive biopsies and the identification of low risk disease. In turn, this
necessitates improved screening to better identify high risk patients within this
population. It is common for men with continued suspicion for disease to undergo
as many as 10 repeat biopsies 90. With advances in MRI technology and the
development of MRI-US fusion biopsy, investigators have explored the utility of
these advances for this population of patients. The results of our analysis
contribute to this discussion.
Multiple authors have compared the performance of MRI-targeted biopsy
with both MRI in-bore and MRI-US fusion approaches to standard TRUS biopsy
for patients with previous negative TRUS biopsies. Hambrock et al first described
significantly higher cancer detection rates of 59% following MRI in-bore targeted
biopsy, as compared to cancer detection rate of 15% in a matched cohort who
received only TRUS biopsy. In the men who were found to have cancer, 48%
were found to have Gleason ≥ 7 disease 94. Continuing this methodology, Hoeks
et al reported a 41% cancer detection rate of in-bore MRI-guided targeted
biopsies in a series of 265 men with elevated PSA and previous negative
systematic TRUS biopsies 95. Meanwhile, other authors have described the
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effectiveness of MRI-US fusion targeted biopsies in these patients. Utilization of
the MRI-US fusion biopsy technology allowed for direct comparison of standard
12-core biopsy cores with targeted biopsy cores in terms of cancer detection.
Vourganti et al reported a targeted biopsy detection rate of 28.72% compared to
23.08% for mapping biopsy in a population of 195 men. Of patients with cancer
found on targeted biopsy, 71.42% were Gleason ≥ 7. Targeted biopsy was found
to upgrade disease in 38.36% of the men with cancer found by either method,
while missing only 5 cases of Gleason 7 disease 97. Sonn et al reported similar
rates of cancer detection 98. Efforts to compare the two targeted biopsy methods
have shown no difference between the two 102. Our findings are consistent with
these rates, with overall cancer detection rate of 42.66%. Targeted biopsy had a
cancer detection rate of 40.5% (67.35% Gleason ≥ 7) compared to 34.97% (52%
Gleason ≥ 7) for mapping biopsy. Targeted biopsy upgraded 21.50% of patients
with cancer found by either method, while missing only 6 cases of Gleason ≥ 7
disease. As with other studies, we did not find any correlation between cancer
detection rate and number of previous biopsies. Our data support the value of
MRI-US fusion biopsy for patients with prior negative TRUS biopsies.
In our analysis, no patients with a negative MRI were found to have
Gleason ≥ 7 disease on standard biopsy. Increased MRI suspicion score was
also correlated with higher grade disease and higher cancer detection rate on
biopsy. Other studies have discussed this relationship between MRI suspicion
score and predicted disease. Utilizing a 5-point Likert scale, Mendhiratta et al
reported that MRI suspicion score < 4 carried a negative predictive value of 96%
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for Gleason ≥ 7 disease. MRI suspicion score ≥ 4 was present in 22 of 26 men
with Gleason ≥ 7, and MRI-US fusion targeted biopsy detected all 22 cases 101.
In our analysis, 25 of the 38 men with Gleason ≥ 7 disease had a high MRI
suspicion score. Though our negative predictive value of low or medium MRI
suspicion score of 85% is not as high as that reported by Mendhiratta et al, we
did have a 100% negative predictive value for negative MRI. Another recent
cohort matched study by Abdi et al utilizing PI-RADS classification found that PIRADS score > 3 was associated with an odds ratio of 15.68 in predicting
presence of Gleason ≥ 7 disease 99. On multivariate regression, we found an
odds ratio of 5.36 for high MRI suspicion score in predicting Gleason ≥ 7 disease.
While this is generally consistent with the findings from Abdi et al, we also found
that high MRI suspicion score lost significance as an independent predictor when
the analysis was divided into presence of significant disease found on each
biopsy method. Our results support the notion that mpMRI has utility in predicting
the presence of clinically significant disease and may even serve as a screening
tool to risk-stratify men in this population.
Beyond MRI suspicion score, our results highlighted the importance of
anterior lesions found on mpMRI. Anterior lesions have been shown to represent
the majority of tumors missed on standard TRUS biopsy 103. Vourganti et al noted
the frequency of anterior tumors found in men with prior negative TRUS biopsies,
diagnosing anterior disease in 33 of the 73 men (45.2%) with cancer 97. Other
authors have investigated this relationship more closely. Volkin et al found a
cancer detection rate of 42.4% for targeted biopsy of anterior lesions in patients
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with prior negative TRUS biopsy versus a 29.3% detection rate with repeated
TRUS biopsy 104. Our analysis found a cancer detection rate of 50.70% for
targeted biopsy of anterior lesions, with 75% of those tumors containing Gleason
≥ 7 disease. This is consistent with the values found by Volkin et al and
comparable to those reported by Schouten et al, who utilized MRI in-bore
targeted biopsy to achieve an overall cancer detection rate of 73%, with 70% of
cancerous lesions located anteriorly and 65% of lesions with Gleason ≥ 7 105. We
also evaluated the predictive value of having an anterior lesion for cancer
detection. While having anterior lesions was not a significant predictor for
clinically significant disease on mapping biopsy, it did predict the presence of
clinically significant disease on targeted biopsy cores with odds ratio of 4.5. This
builds on the idea that some anatomical locations of lesions seen on mpMRI may
be more likely to harbor significant disease in men with previous negative
biopsies. This region of the prostate is poorly sampled on standard TRUS biopsy,
even when repeated multiple times. In this population, men should have some
form of MRI-targeted biopsy to characterize lesions and achieve better sampling
of those in more difficult anatomic positions.
Further investigation of the relationship between clinically significant
disease, MRI suspicion score, and anatomic location of lesions is warranted.
Currently, MRI-targeted biopsy still fails to detect all cases of clinically significant
cancer, confirming the need for continued mapping biopsy in all patients. With
further advances in imaging technology, however, such as the use of contrastenhanced ultrasound by Jang et al, we may be able to better characterize and
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target an even greater proportion of lesions within the gland 106. Optimal risk
stratification of patients with prior negative biopsies will allow for the
differentiation of those with indolent or insignificant disease from those with
aggressive tumors while minimizing morbidity related to repeated prostate
biopsies.
The strengths of this study include the standardized protocol that all
patients in the study period followed. MpMRIs were read and lesions were
graded by one of a panel of radiologists, supporting the reproducibility of our MRI
suspicion score grading system. MRI-US fusion biopsy was performed by a few
experienced operators. Limitations of this study include its retrospective design,
as our data was limited to the information available in patient charts. Many of our
patients are referred from outside providers, and thus we are unable to assume a
standardized technique of TRUS biopsy or pathological reading for previous
biopsies. The potential for selection bias due to referral patterns to our institution
limits the generalizability of our results. Despite these limitations, we believe that
this study contributes to the ongoing discussion of the utility of prebiopsy mpMRI
and MRI-US fusion targeted biopsy in this group of men with previoius negative
biopsies.
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Conclusion
In men with one or more previous negative biopsies and continued suspicion for
prostate cancer, mpMRI and MRI-US fusion targeted biopsy provide greater
detection rate of clinically significant disease compared to standard 12-core
TRUS biopsy. Men with negative MRI findings may be able to avoid or delay
biopsy. Patients with high MRI suspicion score lesions and those with anterior
lesions are at increased risk for significant disease and should be treated with the
necessary diligence. Further investigation into the relationship between mpMRI,
anatomic location of lesions, and effectiveness of MRI-targeted biopsy is required
before broad changes to current practice can be recommended.
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List of Tables
Table 1 Patient Characteristics

Age (mean)
PSA (mean)
Previous Biopsies (mean)
MRI Prostate Volume (mean)
PSA Density (mean)

Total
(n = 143)
64.11
11.59
1.83
68.52
0.20

Cancer
(n = 61)
64.71
13.33
1.74
50.62
0.14

No Cancer
(n = 82)
63.68
10.29
1.89
82.00
0.29

55
24
40
22
141

36 (65.45%)
13 (32.50%)
8 (33.33%)
3 (13.64%)

19 (34.55%)
27 (67.50%)
16 (66.66%)
19 (86.36%)

61

40 (65.57%)

MRIss
High
Moderate
Low
Negative MRI

Has Anterior ROI

p-value
0.386
0.086
0.428
< 0.001
< 0.001

CS Cancer
(n = 39)
66.02
15.61
1.85
51.71
0.16

No CS Cancer
(n = 104)
63.40
10.08
1.82
74.88
0.34

25 (45.45%)
8 (20.00%)
5 (20.83%)
0 (0.00%)

30 (54.55%)
32 (80.00%)
19 (79.17%)
22 (100.00%)

< 0.001
21 (25.61%)

< 0.001

p-value
0.046
0.005
0.893
0.006
< 0.001

< 0.001
27 (69.23%)

34 (32.69%)

< 0.001

Standard TRUS
Biopsy

Table 2 Mapping Biopsy vs Targeted Biopsy

Gleason ≥ 4+3
Gleason 3+4
Gleason 3+3
No Cancer
Totals

MRI-US Fusion Targeted Biopsy
Gleason ≥ 4+3 Gleason 3+4 Gleason 3+3 No Cancer No Target
13
0
0
2
0
1
6
4
0
0
3
5
6
7
3
2
3
6
63
19
19
14
16
72
22

Table 3 MRI Suspicion Score and Biopsy Results

High
Gleason 3+3
Gleason 3+4
Gleason ≥ 4+3
Total

11
19.30%
9
15.79%
16
28.07%
36
63.16%

MRI SS
Moderate
Low
5
3
8.77%
5.26%
6
3
10.53%
5.26%
2
2
3.51%
3.51%
13
8
22.81%
14.04%

Total
19
33.33%
18
31.58%
20
35.09%
57
100.00%

Table 4 Results of Multivariate Logistic Regression

Predictor of CS Cancer on Targeted Biopsy
Age
PSA
Previous Biopsies
Prostate Volume
PSA Density
High Suspicion Lesion
Moderate Suspicion Lesion
Has Anterior ROI

Odds Ratio
1.06
1.02
1.29
0.98
1.03
3.88
1.36
4.50

95% CI
(0.98,1.16)
(0.84, 1.23)
(0.79, 2.12)
(0.95, 1.01)
(0.94, 1.12)
(0.78, 19.28)
(0.23, 7.94)
(1.48, 13.75)

Totals
15
11
24
93
143
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